Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
The FDA expanded ANKTIVA's approved use on October 14, providing a fresh company-specific catalyst. Q2 product revenue grew 92% year over year, and shares gained about 18% over 21 sessions; losses and nearby resistance make this speculative.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Rising Debt ⢠Cash Burn ⢠Negative Equity IBRX's strong near-term liquidity is outweighed by rising debt, negative equity, persistent losses, cash burn, and an elevated sales multiple, suggesting high financing and execution risk.
Price Behavior
Key Price Behavior Insights: ⢠Volatile rebound ⢠Near resistance ⢠Support holding Support Level: $7.90â$8.00 Resistance Level: $8.46â$8.48 IBRX rebounded 9% last month to $8.48, but remains volatile below $8.46â$8.48 resistance, with support at $7.90â$8.00.
Sentiment & News
Key News Insights: ⢠Analyst optimism ⢠Institutional buying ⢠Legal overhang ImmunityBio's momentum, bullish analyst targets and growing institutional stakes support upside, though earnings revisions and class-action risk warrant caution.
AI Summary
IBRX has commercially validated ANKTIVA's demand, but its investment case now depends on sales and label expansions scaling fast enough to offset severe cash burn, $1.23B of debt, and likely dilutionâmaking regulatory execution and financing risk more important than revenue growth alone.
Description
ImmunityBio, Inc. is a clinical-stage biotechnology company developing therapies and vaccines targeting cancers and infectious diseases. The company applies multiple immunotherapy and cell therapy approachesâincluding engineered cytokine fusion proteins, synthetic immunomodulators, and both natural killer and T-cell platformsâand has candidates in Phase II/III trials for solid and liquid tumors (for example, bladder, pancreatic and lung cancers) as well as antiviral programs for pathogens such as SARS-CoV-2 and HIV. It maintains research collaborations and licensing arrangements with U.S. government institutes and several biopharma partners and is headquartered in San Diego, California.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Oct 16 | Oct 23 | IBRX | ImmunityBio, Inc. | The FDA expanded ANKTIVA's approved use on October 14, providing a fresh company-specific catalyst. Q2 product revenue grew 92% year over year, and shares gained about 18% over 21 sessions; losses and nearby resistance make this speculative. | Closed | -10.5% |
| Mar 2 | Mar 9 | IBRX | ImmunityBio, Inc. | ImmunityBio posted ~700% YoY product-revenue growth, secured EU conditional approval and Saudi accelerated approval, and has multiple imminent clinical/label catalysts plus an investor update on 2026-03-03; the share price has climbed ~66% over 21 days and trades well above its 21âday SMA, positioning it as a highârisk but potent short-term momentum play. | Closed | -19.1% |
| Feb 19 | Feb 26 | IBRX | ImmunityBio, Inc. | Multiple recent regulatory wins (EU conditional approval for ANKTIVA+BCG on 2026-02-18, Saudi approval, FDA Type B meeting) plus an EU commercialization deal and accelerating product revenue (~$38M quarter) have driven a >200% month-long rally; momentum remains strong into further catalyst and financing headlines despite high risk. | Closed | +10.9% |
| Jan 16 | Jan 23 | IBRX | ImmunityBio, Inc. | ImmunityBio is a hot idea driven by accelerating commercial revenue growth (700% annual increase in 2025), regulatory approvals expanding markets, positive clinical data mid-January 2026, nearly doubled stock price in past month, despite ongoing financial risks. | Closed | +16.9% |